PMV Pharmaceuticals, Inc.
No SEC Form 4 filings for $PMVP in the last 30 days.
See all $PMVP insider activity →Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.
PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 PMV Pharma Announces Pricing of Oversubscribed $50Million Public Offering of Securities PRINCETON, N.J. , August 31, 2026 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery
PMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2026 results and clinical updates. Enrollment for the Phase 2 monotherapy primary analysis in its PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer is complete. The company plans an NDA for accelerated approval in Q1 2027. Cash, cash equivalents and marketable securities were $79.4M at June 30, 2026, with net loss $18.1M.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PMVP (PMV Pharmaceuticals, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PMVP coverage spans financial news, corporate actions and technology.
Early positive trial data may spark speculative buying in the oncology space.
The capital raise will provide near‑term funding but dilutes existing shareholders; short‑term price pressure expected.
Clinical and regulatory timeline progress for rezatapopt (TP53 Y220C ovarian cancer) is the key incremental catalyst for PMVP.
Near-term catalyst is the planned Q1 2027 NDA submission for rezatapopt accelerated approval in TP53 Y220C platinum-resistant/refractory ovarian cancer, alongside cash runway guidance.
PMV Pharmaceuticals is approaching a pivotal period in Q1 2026, with key events potentially influencing its stock performance. The company's success in meeting enrollment targets and upcoming financial disclosures are critical.
AlphAI scores every news story that mentions PMVP with an AI model for sentiment and relevance, and aggregates insider trades from PMV Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.
2 min readPMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 PMV Pharma Announces Pricing of Oversubscribed $50Million Public Offering of Securities PRINCETON, N.J. , August 31, 2026 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery
1 min readPMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2026 results and clinical updates. Enrollment for the Phase 2 monotherapy primary analysis in its PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer is complete. The company plans an NDA for accelerated approval in Q1 2027. Cash, cash equivalents and marketable securities were $79.4M at June 30, 2026, with net loss $18.1M.
4 min readPMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed • Rez
6 min readPMV Pharmaceuticals is entering a crucial first quarter of 2026 with several key events for its lead cancer therapy, rezatapopt. Investors are focused on upcoming financial results, a presentation at the TD Cowen Health Care Conference, and the critical completion of patient enrollment for its platinum-resistant ovarian cancer study. Meeting the enrollment target by late March 2026 is essential for the company's planned New Drug Application submission by Q1 2027.
4 min readData presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma
3 min readPRINCETON, N.J., Oct. 24, 2025 ( GLOBE NEWSWIRE ) -- PMV Pharmaceuticals, Inc. ( "PMV Pharma" or the "Company". Nasdaq: PMVP ) , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced updated data from the ...
3 min read33% overall response rate in patients with TP53 Y220C mutation across eight tumor types. Median time to response: 1.4 months; median duration of response: 6.2 months. Get the data-driven signals to profit from September volatility ( for free ) → PMV Pharmaceuticals, Inc.
2 min readPMV Pharmaceuticals ( NASDAQ:PMVP ) , a biotechnology company focused on precision oncology, reported its second quarter 2025 earnings on August 7, 2025. The most notable update was the continued operational investment in its lead asset, rezatapopt, now in a pivotal Phase 2 clinical trial.
4 min readPRINCETON, N.J., May 23, 2025 ( GLOBE NEWSWIRE ) -- PMV Pharmaceuticals, Inc. ( "PMV Pharma". Nasdaq: PMVP ) , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H.
2 min read
